Microbiota, Liver Diseases, and Alcohol.

Area of Science:

• Gastroenterology and Hepatology
• Microbiology
• Metabolic Diseases

Background:

• Obesity and alcohol consumption are primary drivers of liver disease, including steatosis, steatohepatitis, fibrosis, cirrhosis, and cancer.
• Not all individuals with obesity or high alcohol intake develop advanced liver disease, suggesting other contributing factors.
• The intestinal microbiota (IM) is increasingly recognized for its role in liver disease susceptibility.

Purpose of the Study:

• To investigate the influence of the intestinal microbiota on the development of liver disease in the context of obesity and alcohol consumption.
• To explore the mechanisms by which gut dysbiosis contributes to metabolic liver diseases.
• To evaluate the potential of targeting the IM for liver disease prevention and therapy.

Main Methods:

• Analysis of studies examining the composition of the intestinal microbiota in rodent models and human cohorts with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).
• Investigation of microbial metabolites, such as short-chain fatty acids and bile acids, associated with dysbiosis.
• Review of research on the effects of probiotics and prebiotics on liver disease parameters.

Main Results:

• Dysbiosis of the intestinal microbiota is associated with both NAFLD and ALD.
• Specific microbial metabolites are linked to gut dysbiosis and liver disease.
• Modulation of the IM, through interventions like probiotics and prebiotics, shows promise in improving liver disease parameters.

Conclusions:

• The intestinal microbiota plays a causal role in the development of metabolic liver diseases.
• There is an intimate relationship between the gut microbiota and liver health.
• Targeting the gut microbiota represents a potential novel strategy for the prevention and treatment of liver diseases.